Study #2022-0990
An open-label, Phase 1b study to evaluate the safety and tolerability of eflornithine plus temozolomide in patients with newly diagnosed glioblastoma
MD Anderson Study Status
Enrolling
Treatment Agent
Eflornithine (Dose Level 1), Temozolomide, Eflornithine (Dose Level 2), Eflornithine (Dose Level -1)
Description
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM
Study phase:
Phase I
Physician name:
Carlos Kamiya Matsuoka
Department:
Neuro-Oncology
For general questions about clinical trials:
1-844-274-8956
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.